Skip to main content
SpringerLink
Log in

Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks

  • Chapter
  • First Online:
Reflux Aspiration and Lung Disease

Abstract

Gastro-esophageal reflux (i.e. the reflux of gastric contents into the esophagus, GER) is a physiological phenomenon, occurring in everybody, especially after large and fat meals. Under physiologic conditions, efficient esophageal clearing mechanisms return most of the refluxed material to the stomach and symptoms do not occur [1]. However, when the reflux of gastric contents is large or aggressive enough, it causes symptoms and/or complications and impairs quality of life, giving rise to GER disease (GERD) [2]. According to the Montreal definition [3], GERD is a chronic condition which develops when the reflux of stomach contents causes troublesome and recurrent symptoms (which could be typical, i.e. esophageal or/and atypical, i.e. extra-esophageal), and/or complications, which include esophagitis, ulcer, stricture and Barrett’s esophagus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kahrilas PJ. GERD pathogenesis, pathophysiology, and clinical manifestations. Cleve Clin J Med. 2003;70(Suppl 5):S4–19.

    Article  PubMed  Google Scholar 

  2. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management—the Genval Workshop Report. Gut. 1999;44(Suppl 2):S1–16.

    Article  PubMed Central  Google Scholar 

  3. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20; quiz 43.

    Article  PubMed  Google Scholar 

  4. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–80.

    Article  PubMed  Google Scholar 

  5. Modlin IM, Hunt RH, Malfertheiner P, et al. Diagnosis and management of non-erosive reflux disease—the Vevey NERD Consensus Group. Digestion. 2009;80:74–88.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119–24.

    Article  PubMed  CAS  Google Scholar 

  7. Galmiche JP, Letessier E, Scarpignato C. Treatment of gastro-oesophageal reflux disease in adults. BMJ. 1998;316:1720–3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Wang C, Hunt RH. Medical management of gastroesophageal reflux disease. Gastroenterol Clin N Am. 2008;37:879–99, ix.

    Article  Google Scholar 

  9. Savarino V, Scarpignato C. Novità in tema di fisiopatologia della malattia da reflusso gastroesofageo—quale ruolo degli alginati nell’era degli inibitori della pompa protonica? Ther Perspect. 2011;14:1–37.

    Google Scholar 

  10. Boeckxstaens GE, Rohof WO. Pathophysiology of gastroesophageal reflux disease. Gastroenterol Clin N Am. 2014;43:15–25.

    Article  Google Scholar 

  11. Kahrilas PJ, McColl K, Fox M, et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol. 2013;108:1058–64.

    Article  PubMed  CAS  Google Scholar 

  12. Anand G, Katz PO. Gastroesophageal reflux disease and obesity. Gastroenterol Clin N Am. 2010;39:39–46.

    Article  Google Scholar 

  13. Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin N Am. 2014;43:161–73.

    Article  Google Scholar 

  14. Kahrilas PJ, Boeckxstaens G. Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients? Gut. 2012;61:1501–9.

    Article  PubMed  Google Scholar 

  15. Looijer-van Langen M, Veldhuyzen van Zanten S. Does the evidence show that prokinetic agents are effective in healing esophagitis and improving symptoms of GERD? Open Med. 2007;1:e181–3.

    PubMed  PubMed Central  Google Scholar 

  16. Weijenborg PW, de Schepper HS, Smout AJ, Bredenoord AJ. Effects of antidepressants in patients with functional esophageal disorders or gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2015;13:251–59.e1.

    Article  PubMed  CAS  Google Scholar 

  17. Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1350–65; quiz 66.

    Article  PubMed  CAS  Google Scholar 

  18. Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: where do we go from here? Dig Dis. 2006;24:11–46.

    Article  PubMed  Google Scholar 

  19. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59:135–53.

    Article  PubMed  CAS  Google Scholar 

  20. Moayyedi P, Santana J, Khan M, Preston C, Donnellan C. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007:CD003244.

    Google Scholar 

  21. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis—a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther. 2006;24:743–50.

    Article  PubMed  CAS  Google Scholar 

  22. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452–8.

    Article  PubMed  CAS  Google Scholar 

  23. Labenz J, Armstrong D, Leodolter A, Baldycheva I. Management of reflux esophagitis: does the choice of proton pump inhibitor matter? Int J Clin Pract. 2015;69:796–801.

    Article  PubMed  CAS  Google Scholar 

  24. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111:85–92.

    Article  PubMed  CAS  Google Scholar 

  25. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–80.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol. 2015;6:e119.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Iwakiri K, Umegaki E, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (20 mg once-daily) compared to lansoprazole (30 mg once-daily) in patients with erosive esophagitis. Gastroenterology. 2014;146:S-741.

    Article  Google Scholar 

  28. Umegaki E, Iwakiri K, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg once-daily) compared to lansoprazole (15 mg once-daily) in a 24-week maintenance treatment for healed erosive esophagitis. Gastroenterology. 2014;146:S-738.

    Article  Google Scholar 

  29. Goldstein JL, Miner PB Jr, Schlesinger PK, Liu S, Silberg DG. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther. 2006;23:1189–96.

    Article  PubMed  CAS  Google Scholar 

  30. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65:19–31.

    Article  PubMed  CAS  Google Scholar 

  31. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013:CD002095.

    Google Scholar 

  32. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1419–25.

    Article  PubMed  Google Scholar 

  33. Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747–57.

    Article  PubMed  CAS  Google Scholar 

  34. Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol. 2013;10:371–80.

    Article  PubMed  CAS  Google Scholar 

  35. Scarpignato C. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil. 2012;24:697–704.

    Article  PubMed  CAS  Google Scholar 

  36. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Esophageal disorders. Gastroenterology. 2016;150:1368–79.

    Article  Google Scholar 

  37. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis—a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635–43.

    Article  PubMed  CAS  Google Scholar 

  38. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473–7.

    Article  PubMed  CAS  Google Scholar 

  39. Scarpignato C, Pelosini I. Review article: the opportunities and benefits of extended acid suppression. Aliment Pharmacol Ther. 2006;23(Suppl 2):23–34.

    Article  PubMed  CAS  Google Scholar 

  40. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18:370–3.

    Article  PubMed  CAS  Google Scholar 

  41. Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev. 2009:CD004275.

    Google Scholar 

  42. Scarpignato C. Antisecretory drugs, helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle. Dig Liver Dis. 2005;37:468–74.

    Article  PubMed  CAS  Google Scholar 

  43. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005:CD003245.

    Google Scholar 

  44. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. J Outcomes Res. 2002;6:1–14.

    Google Scholar 

  45. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011;305:1969–77.

    Article  PubMed  CAS  Google Scholar 

  46. Lundell L, Miettinen P, Myrvold HE, et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009;7:1292–8.

    Article  PubMed  Google Scholar 

  47. Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol. 2010;24:905–21.

    Article  PubMed  CAS  Google Scholar 

  48. Contini S, Scarpignato C. Evaluation of clinical outcome after laparoscopic antireflux surgery in clinical practice: still a controversial issue. Minim Invasive Surg. 2011;2011:725472.

    PubMed  PubMed Central  Google Scholar 

  49. Yuan Y, Dattani ND, Scarpignato C, Hunt RH. Use of antisecretory medication after antireflux surgery for patients with gastroesophageal reflux disease (GERD): a systematic review of randomized control trials (RCTs). Am J Gastroenterol. 2009;104(Suppl 3):S25.

    Google Scholar 

  50. Yuan Y, Dattani ND, Scarpignato C, Hunt RH. Use of antisecretory medication (ARM) after antireflux surgery (ARS) for patients with gastroesophageal reflux disease (GERD): a systematic review of non-randomized studies. Gut. 2010;59(Suppl 1):A116–A17.

    Google Scholar 

  51. Rohof WO, Bisschops R, Tack J, Boeckxstaens GE. Postoperative problems 2011: fundoplication and obesity surgery. Gastroenterol Clin N Am. 2011;40:809–21.

    Article  CAS  Google Scholar 

  52. Richter JE. Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroenterol Hepatol. 2013;11:465–71.

    Article  PubMed  Google Scholar 

  53. Lin DC, Chun CL, Triadafilopoulos G. Evaluation and management of patients with symptoms after anti-reflux surgery. Dis Esophagus. 2015;28:1–10.

    Article  PubMed  Google Scholar 

  54. Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbol DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014;31:625–30.

    Article  PubMed  Google Scholar 

  55. Lodrup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol. 2013;48:515–22.

    Article  PubMed  CAS  Google Scholar 

  56. de Bortoli N, Guidi G, Martinucci I, et al. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study. Dis Esophagus. 2016;29:197–204.

    Article  PubMed  Google Scholar 

  57. Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.

    Article  PubMed  CAS  Google Scholar 

  58. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–91.

    Article  PubMed  Google Scholar 

  59. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.

    Article  PubMed  Google Scholar 

  60. Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–37.

    Article  PubMed  Google Scholar 

  61. Akiyama J, Bertele A, Brock C, et al. Benign and precursor lesions in the esophagus. Ann N Y Acad Sci. 2014;1325:226–41.

    Article  PubMed  Google Scholar 

  62. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6.

    Article  PubMed  CAS  Google Scholar 

  63. World Gastroenterology Organisation Global Guidelines. GERD: Global Perspective on Gastroesophageal Reflux Disease. 2015. http://www.worldgastroenterology.org/guidelines/globalguidelines/gastroesophageal-reflux-disease/gastroesophageal-reflux-disease-english.

  64. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42:649–63.

    Article  PubMed  CAS  Google Scholar 

  65. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–28.

    Article  PubMed  Google Scholar 

  66. Jaspersen D, Kulig M, Labenz J, et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD study. Aliment Pharmacol Ther. 2003;17:1515–20.

    Article  PubMed  CAS  Google Scholar 

  67. Francis DO, Rymer JA, Slaughter JC, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013;108:905–11.

    Article  PubMed  Google Scholar 

  68. Vaezi MF. Benefit of acid-suppressive therapy in chronic laryngitis: the devil is in the details. Clin Gastroenterol Hepatol. 2010;8:741–2.

    Article  PubMed  Google Scholar 

  69. de Bortoli N, Nacci A, Savarino E, et al. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related? World J Gastroenterol. 2012;18:4363–70.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Mazzoleni G, Vailati C, Lisma DG, Testoni PA, Passaretti S. Correlation between oropharyngeal pH-monitoring and esophageal pH-impedance monitoring in patients with suspected GERD-related extra-esophageal symptoms. Neurogastroenterol Motil. 2014;26:1557–64.

    Article  PubMed  CAS  Google Scholar 

  71. Burgstaller JM, Jenni BF, Steurer J, Held U, Wertli MM. Treatment efficacy for non-cardiovascular chest pain: a systematic review and meta-analysis. PLoS One. 2014;9:e104722.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Roman C, Bruley des Varannes S, Muresan L, Picos A, Dumitrascu DL. Atrial fibrillation in patients with gastroesophageal reflux disease: a comprehensive review. World J Gastroenterol. 2014;20:9592–9.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev. 2011:CD004823.

    Google Scholar 

  74. Kahrilas PJ, Howden CW, Hughes N, Molloy-Bland M. Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease. Chest. 2013;143:605–12.

    Article  PubMed  CAS  Google Scholar 

  75. Sen P, Georgalas C, Bhattacharyya AK. A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux. Clin Otolaryngol. 2006;31:20–4.

    Article  PubMed  CAS  Google Scholar 

  76. Qadeer MA, Colabianchi N, Strome M, Vaezi MF. Gastroesophageal reflux and laryngeal cancer: causation or association? A critical review. Am J Otolaryngol. 2006;27:119–28.

    Article  PubMed  Google Scholar 

  77. Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil N. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25:385–92.

    Article  PubMed  CAS  Google Scholar 

  78. Guo H, Ma H, Wang J. Proton pump inhibitor therapy for the treatment of laryngopharyngeal reflux: a meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2016;50:295–300.

    Article  PubMed  CAS  Google Scholar 

  79. Wei C. A meta-analysis for the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2016;273:3795.

    Article  PubMed  Google Scholar 

  80. Liu C, Wang H, Liu K. Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux. Braz J Med Biol Res. 2016;49:S0100-879X2016000700704.

    PubMed  Google Scholar 

  81. Harding SM. Gastroesophageal reflux, asthma, and mechanisms of interaction. Am J Med. 2001;111(Suppl 8A):8S–12S.

    Article  PubMed  Google Scholar 

  82. Scarpignato C. Pharmacological bases of the medical treatment of gastroesophageal reflux disease. Dig Dis. 1988;6:117–48.

    Article  PubMed  CAS  Google Scholar 

  83. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003:CD001496.

    Google Scholar 

  84. Ranjitkar S, Smales RJ, Kaidonis JA. Oral manifestations of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2012;27:21–7.

    Article  PubMed  CAS  Google Scholar 

  85. Wilder-Smith CH, Wilder-Smith P, Kawakami-Wong H, Voronets J, Osann K, Lussi A. Quantification of dental erosions in patients with GERD using optical coherence tomography before and after double-blind, randomized treatment with esomeprazole or placebo. Am J Gastroenterol. 2009;104:2788–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Khalil HS. The diagnosis and management of globus: a perspective from the United Kingdom. Curr Opin Otolaryngol Head Neck Surg. 2008;16:516–20.

    Article  PubMed  Google Scholar 

  87. Kahrilas PJ, Shaheen NJ, Vaezi MF, American Gastroenterological Association Institute, Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392–413.

    Article  PubMed  Google Scholar 

  88. Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg. 2002;127:32–5.

    Article  PubMed  Google Scholar 

  89. Irwin RS. Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:80s–94s.

    Article  PubMed  Google Scholar 

  90. Altman KW, Prufer N, Vaezi MF. A review of clinical practice guidelines for reflux disease: toward creating a clinical protocol for the otolaryngologist. Laryngoscope. 2011;121:717–23.

    Article  PubMed  Google Scholar 

  91. Hunt R. Acid suppression for reflux disease: “off-the-peg” or a tailored approach? Clin Gastroenterol Hepatol. 2012;10:210–3.

    Article  PubMed  Google Scholar 

  92. Glicksman JT, Mick PT, Fung K, Carroll TL. Prokinetic agents and laryngopharyngeal reflux disease: prokinetic agents and laryngopharyngeal reflux disease: a systematic review. Laryngoscope. 2014;124:2375–9.

    Article  PubMed  Google Scholar 

  93. Ezzat WF, Fawaz SA, Fathey H, El Demerdash A. Virtue of adding prokinetics to proton pump inhibitors in the treatment of laryngopharyngeal reflux disease: prospective study. J Otolaryngol Head Neck Surg. 2011;40:350–6.

    PubMed  Google Scholar 

  94. Chun BJ, Lee DS. The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease. Eur Arch Otorhinolaryngol. 2013;270:1385–90.

    Article  PubMed  Google Scholar 

  95. Poe RH, Kallay MC. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. Chest. 2003;123:679–84.

    Article  PubMed  Google Scholar 

  96. Dabirmoghaddam P, Amali A, Motiee Langroudi M, Samavati Fard MR, Hejazi M, Sharifian Razavi M. The effect of N-acetyl cysteine on laryngopharyngeal reflux. Acta Med Iran. 2013;51:757–64.

    PubMed  CAS  Google Scholar 

  97. McGlashan JA, Johnstone LM, Sykes J, Strugala V, Dettmar PW. The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2009;266:243–51.

    Article  PubMed  Google Scholar 

  98. Lieder A, Issing W. Treatment for resilient cough owing to laryngopharyngeal reflux with a combination of proton pump inhibitor and Gaviscon(R) Advance: how we do it. Clin Otolaryngol. 2011;36:583–7.

    Article  PubMed  CAS  Google Scholar 

  99. Strugala V, Dettmar PW. Alginate in the treatment of extra-oesophageal reflux. In: Johnson N, Toohill RJ, editors. Effects, diagnosis and management of extra-esophageal reflux. New York: Nova Science; 2010. p. 145–68.

    Google Scholar 

  100. Zentilin P, Dulbecco P, Savarino E, et al. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. Aliment Pharmacol Ther. 2005;21:29–34.

    Article  PubMed  CAS  Google Scholar 

  101. Strugala V, Avis J, Jolliffe IG, Johnstone LM, Dettmar PW. The role of an alginate suspension on pepsin and bile acids—key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease? J Pharm Pharmacol. 2009;61:1021–8.

    Article  CAS  PubMed  Google Scholar 

  102. Bardhan KD, Strugala V, Dettmar PW. Reflux revisited: advancing the role of pepsin. Int J Otolaryngol. 2012;2012:646901.

    Article  PubMed  Google Scholar 

  103. Di Simone MP, Baldi F, Vasina V, et al. Barrier effect of Esoxx((R)) on esophageal mucosal damage: experimental study on ex-vivo swine model. Clin Exp Gastroenterol. 2012;5:103–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Palmieri B, Merighi A, Corbascio D, Rottigni V, Fistetto G, Esposito A. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux. Eur Rev Med Pharmacol Sci. 2013;17:3272–8.

    PubMed  CAS  Google Scholar 

  105. Savarino V, Pace F, Scarpignato C. Randomized clinical trial: mucosal protection combined with acid suppression in the treatment of nor erosive reflux disease—efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45:631–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Contini S, Scarpignato C. Endoscopic treatment of gastro-oesophageal reflux disease (GORD): a systematic review. Dig Liver Dis. 2003;35:818–38.

    Article  PubMed  CAS  Google Scholar 

  107. Blandizzi C, Scarpignato C. Gastrointestinal drugs. In: Aronson JK, editor. Side effects of drugs annual, Chap. 36. Amsterdam: Elsevier; 2011. p. 741–67.

    Google Scholar 

  108. Blandizzi C, Scarpignato C. Gastrointestinal drugs. In: Aronson JK, editor. Side effects of drugs annual, Chap. 36. Amsterdam: Elsevier; 2012. p. 555–78.

    Chapter  Google Scholar 

  109. Blandizzi C, Scarpignato C. Gastrointestinal drugs. In: Aronson JK, editor. Side effects of drugs annual, Chap. 36. Amsterdam: Elsevier; 2014. p. 633–58.

    Google Scholar 

  110. Blandizzi C, Scarpignato C. Gastrointestinal drugs. In: Sidhartha DR, editor. Side effects of drugs annual, Chap. 36. Amsterdam: Elsevier; 2014. p. 539–60.

    Google Scholar 

  111. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448–57.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931–50.

    Article  PubMed  CAS  Google Scholar 

  114. Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012;46:93–114.

    Article  PubMed  CAS  Google Scholar 

  115. Johnson DA, Oldfield EC. Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol. 2013;11:458–64.

    Article  PubMed  Google Scholar 

  116. de la Coba Ortiz C, Arguelles Arias F, Martin de Argila de Prados C, et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Espanola de Patologia Digestiva. Rev Esp Enferm Dig. 2016;108:207–24.

    Article  PubMed  Google Scholar 

  117. Mossner J. The indications, applications, and risks of proton pump inhibitors. Dtsch Arztebl Int. 2016;113:477–83.

    PubMed  PubMed Central  Google Scholar 

  118. Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis. 2016;48:851–9.

    Article  PubMed  CAS  Google Scholar 

  119. Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153:35–48.

    Article  PubMed  CAS  Google Scholar 

  120. Lahner E, Annibale B, Delle Fave G. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther. 2009;29:1219–29.

    Article  PubMed  CAS  Google Scholar 

  121. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29:769–84.

    Article  PubMed  CAS  Google Scholar 

  122. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37:201–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  123. Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Saf. 2016;15:223–36.

    Article  PubMed  CAS  Google Scholar 

  124. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935–51.

    Article  PubMed  CAS  Google Scholar 

  125. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913–58.

    Article  CAS  PubMed  Google Scholar 

  126. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34:1708–13.

    Article  PubMed  Google Scholar 

  127. Cardoso RN, Benjo AM, DiNicolantonio JJ, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015;2:e000248.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Leontiadis GI, Yuan Y, Howden CW. The interaction between proton pump inhibitors and clopidogrel and upper gastrointestinal bleeding. Gastrointest Endosc Clin N Am. 2011;21:637–56.

    Article  PubMed  Google Scholar 

  129. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleve Clin J Med. 2011;78:39–49.

    Article  PubMed  Google Scholar 

  130. Vaduganathan M, Cannon CP, Cryer BL, et al. Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial. Am J Med. 2016;129:1002–5.

    Article  PubMed  CAS  Google Scholar 

  131. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–17.

    Article  PubMed  CAS  Google Scholar 

  132. Vaduganathan M, Bhatt DL, Cryer BL, et al. Proton-pump inhibitors reduce gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy. J Am Coll Cardiol. 2016;67:1661–71.

    Article  PubMed  CAS  Google Scholar 

  133. Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41:1162–74.

    Article  PubMed  CAS  Google Scholar 

  134. Fiocca R, Mastracci L, Attwood SE, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther. 2012;36:959–71.

    Article  PubMed  CAS  Google Scholar 

  135. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 2012;72:437–45.

    Article  PubMed  CAS  Google Scholar 

  136. Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases—a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology and Digestive Pathophysiology Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy

    Carmelo Scarpignato & Luigi Gatta

  2. Gastroenterology and Endoscopy Unit, Versilia Hospital, Azienda USL Toscana Nord Ovest, Lido di Camaiore, Italy

    Luigi Gatta

Authors
  1. Carmelo Scarpignato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luigi Gatta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmelo Scarpignato .

Editor information

Editors and Affiliations

  1. University of Hull, Hull York Medical School, Cottingham, East Yorkshire, United Kingdom

    Alyn H. Morice

  2. Castle Hill Hospital, RD Biomed Limited, Cottingham, East Yorkshire, United Kingdom

    Peter W. Dettmar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Scarpignato, C., Gatta, L. (2018). Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. In: Morice, A., Dettmar, P. (eds) Reflux Aspiration and Lung Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-90525-9_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90525-9_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90523-5

  • Online ISBN: 978-3-319-90525-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation